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Dry Eye Diseases and Ocular Surgery: Practical Guidelines  
for Canadian Eye Care Practitioners
ABSTRACT:
In 2014, the Canadian Dry Eye Disease Consensus Panel published Guidelines 
for screening, diagnosis and management of dry eye diseases (DED). These did 
not address the implications of DED for individuals who are being considered 
for or have recently undergone ocular surgery. DED is common in certain 
surgical cohorts, and the perisurgical setting poses specific challenges, both 
because surgery can complicate preexisting DED and because symptomatic 
and non-symptomatic DED place the patient at risk of poor surgical outcomes. 
The Consensus Panel has developed this Addendum to the 2014 Guidelines to 
offer guidance on DED care before and after ocular surgery.
SHORT TITLE: 
Perisurgical Dry Eye Disease
CORRESPONDING AUTHOR:
Paul M. Karpecki, OD, FAAO, Kentucky Eye Institute, 601 Perimeter Dr., 
Ste. 100, Lexington KY 40517, Tel: 859 278-9393, Fax: 859 277-3965, E-mail: 
paul@karpecki.com
KEY WORDS: 
Dry eye disease, keratoconjunctivitis sicca, phacoemulsification, LASIK, 
quality of vision, ocular neuropathic pain
for the Canadian Dry Eye Disease 
Consensus Panel
Paul M. Karpecki, OD, FAAO
Kentucky Eye Institute, University 
of Pikeville School of Optometry 
C. Lisa Prokopich, OD, MSc
University of Waterloo,  
School of Optometry  
and Vision Science
Louis Racine, MD, FRCSC
Université de Montréal, Faculté 
de médecine, Département 
d’ophtalmologie 
Etty Bitton, OD, MSc, FAAO
Université de Montréal,  
École d’optométrie
Barbara Caffery, OD, PhD
Toronto Eye Care
Paul Harasymowycz, MD, 
FRCSC
Montreal Glaucoma Institute
Langis Michaud, OD, MSc, 
FAAO
Université de Montréal,  
École d’optométrie
Victor D. Pegado, MD, 
FRCSC, Dipl. ABO
University of British Columbia, 
Faculty of Medicine, Department 
of Ophthalmology and Visual 
Sciences 
Jean-Sébastien Dufour,  
OD, MSc
Université de Montréal,  
École d’optométrie 
Paul Neumann, OD
Central Saanich Optometry 
Andrew Webber, OD
Elmsdale Vision Centre 
John Ashkenas, PhD
SCRIPT 
CLINICAL RESEARCH C
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  4 19
CLINICAL RESEARCHC
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  420
INTRODUCTION
Dry Eye Disease and the 2014 Canadian Guidelines
Dry eye disease (DED), also known as keratoconjunctivitis sicca, comprises a group of inflammatory ocular-
surface diseases that, collectively, are ubiquitous1, 2 in the general population. DED is highly prevalent in specific 
subpopulations, including adults over age 50,1 women, people with long-standing diabetes,3 and people who wear 
contact lenses.4, 5 Rarer conditions associated with severe DED include Sjögren syndrome (SS),6 Steven-Johnson 
syndrome, nocturnal lagophthalmos, exposure keratopathy, and graft-versus-host disease.7, 8
DED encompasses multiple conditions in which the precorneal tear film is scarce, unstable, inadequately dis-
tributed, or of abnormal composition. For instance, tears may be deficient in lipids (Meibomian gland dysfunc-
tion, a common cause of evaporative DED), water (e.g., in SS), or mucins (e.g., due to genetic deficiency or 
loss of conjunctival goblet cell function).8 Tears in DED become hyperosmolar and may accumulate cytokines 
that trigger and perpetuate local inflammation. Hyperosmolar tears can damage the corneal and conjunctival 
epithelia, in part because they carry high levels of inflammatory mediators, such as the degradative enzyme 
matrix metalloproteinase-9.9
DED may present with any combination of ocular dryness, fatigue, redness, burning, itching or stinging pain, for-
eign-body sensation, and light sensitivity, as well as mucus filaments, eyelid irritation and crusting. Patients may 
report blurred or fluctuating vision and may experience reduced visual acuity and impaired functioning in visual 
tasks. Use of dyes for ocular-surface staining during routine exams often detects conjunctival and corneal abnor-
malities such as superficial punctate keratitis.10 In extreme cases, DED can lead to corneal ulceration, neovascular-
ization, permanent scarring, and irreversible visual loss.11
OCUL AR NEUROPATHIC PAIN
Patients who suffer from neuropathic eye pain may describe their subjective experience in terms similar 
to those used for DED. Common pain descriptors used for both conditions include “burning,” “sharp,” and 
“gritty,” and both can cause light sensitivity. This similarity of presentation frequently leads to confusion 
and treatment dissatisfaction, particularly for individuals who develop persistent or intractable postsurgical 
pain.24, 89
The origins of neuropathic pain are obscure, but nerve damage from various sources may be a proximate 
cause.23, 34, 90 Aberrant nerve regeneration and several other central and peripheral neurologic events22 have 
been proposed to reinforce the neuropathy, causing the pain to become chronic.24, 89
Eye pain may be identified for the first time as neuropathic following surgery. However, neuropathic ocular 
pain is also widely found in patients with no history of ocular surgery. Pain reported after surgery sometimes 
follows a pre-existing pattern that might have been misattributed to DED or other causes. A neuropathic 
origin should be suspected when ocular hypersensitivity, hyperalgesia (exaggerated pain response to supra-
threshold noxious stimuli), or allodynia (pain in response to normally non-noxious stimuli) are not com-
mensurate with objective signs of DED, such as corneal and conjunctival staining.
This possibility can be tested by instilling anesthetic drops, thus blunting nociceptive signals from corneal 
neurons.22, 24 By definition, neuropathic pain originates in the brainstem or elsewhere in the central nervous 
system. Therefore, although this test is not diagnostic, the observation of pain that persists despite topical 
anesthesia is suggestive of neuropathy. Neuropathic pain is also reported to be poorly responsive to artificial 
tears, relative to physiologic (nociceptive) pain.91
Common comorbidities include general (non-ocular) neuropathic pain, as well as depression, anxiety, and 
sleep disturbance;22, 92, 93 patients reporting otherwise-unexplained eye pain should be queried about these 
other conditions as well.
RESEARCH
In 2014, the Canadian Dry Eye Disease Consensus Panel presented Guidelines on DED screening, diagnosis and man-
agement.8 This guidance (Fig. 1) offered general principles for diagnosing and managing episodic, chronic, and recal-
citrant DED and for monitoring the effectiveness of treatment. Based on these Guidelines, it is essential for all eye care 
professionals to screen for ocular-surface diseases and manage them appropriately. As discussed in the Guidelines, epi-
sodic DED can sometimes be managed with lubricating eye drops, eyelid hygiene, and/or modifications to the living and 
working environment. Conversely, chronic DED is an inflammatory disease that requires anti-inflammatory treatment.8 
Currently available options to manage ocular-surface inflammation include topical corticosteroids, which are generally 
reserved for short-term use, as well as essential fatty acids and cyclosporine 0.05% emulsion in castor oil (Restasis®, Al-
lergan Inc.; throughout this Addendum, cyclosporine refers to this formulation).8 Additional topical anti-inflammatory 
products, such as lifitegrast 5% and cyclosporine 0.1% in a cationic formulation, may soon reach the Canadian market for 
use in cases of DED.12-17 To date, there have been no reports on the perisurgical use of these additional products.
Figure 1: Diagnosis and management of DED, according to the 2014 Canadian Guidelines8
Scope and Aims of this Addendum
The 2014 Guidelines did not address DED management in individuals undergoing ocular surgery. This topic is 
significant because of the variety of ways that uncontrolled DED can become problematic for patients undergoing 
procedures such as cataract surgery or refractive surgery. In addition, ocular surgeries of many types (Table 1) can 
induce ocular-surface inflammation, which results from direct trauma to the cornea, light toxicity from the surgical 
microscope, tear-film evaporation during surgery, and irritation due to topical anesthetics, surface antiseptic solu-
tions, and preservative-containing eye drops.18-21 As a result, surgery can precipitate de novo DED or exacerbate the 
condition in patients with pre-existing symptomatic or asymptomatic DED. Postsurgical ocular dryness and pain 
that present during the recovery phase are usually transient, but can persist in certain individuals. Chronic pain 
without significant ocular-surface disease (“pain without stain”)22 can also occur, and may be present before or after 
surgery; such neuropathic eye pain, resulting from lesions within the somatosensory nervous system,23 is not readily 
distinguished from DED. This confusion poses a variety of clinical problems that can be frustrating for both patients 
and caregivers (see sidebar on Ocular Neuropathic Pain).22, 24
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As discussed below, pre-existing ocular-surface disease complicates presurgical biometry, keratometry, topog-
raphy and refraction, thus increasing a patient’s risk of unsatisfactory visual correction and of refractive re-
gression. DED can degrade the quality of vision (QoV) after surgery, leading to discomfort and dissatisfaction, 
even among patients whose visual acuity has been corrected effectively. Conversely, measures that restore the 
tear film, reduce tear osmolarity, or suppress corneal and conjunctival inflammation may improve postsurgical 
DED symptoms and visual outcomes. Thus, there are several compelling reasons to manage DED, both before 
and after surgery. Nevertheless, in surgical candidates and others, ocular-surface disease frequently goes un-
recognized and untreated.8, 25 It is crucial for eye care professionals to recognize DED signs and symptoms in 
surgical candidates, to begin treatment promptly, and wherever possible, to reverse ocular-surface inflamma-
tion before proceeding to surgery.
Table 1: Ocular surgeries that may require DED diagnosis and management
Type of surgery
Surgery induces or 
complicates DED?
DED complicates 
surgery?
DED highly 
prevalent in surgical 
cohort?
References
Refractive
LASIK Yes Yes Yes This article
PRK Yes Yes Yes 110
Cataract
Phacoemulsification Yes Yes Yes This article
Corneal/conjunctival
Penetrating keratoplasty Yes Yes Yes 111-113
Endothelial keratoplasty Yes Yes Yes 111-114
Pterygium excision Yes No Yes 115
Conjunctivochalasis removal No Yes Yes 116-119
Vitreo-retinal
Vitrectomy Yes ? Yes 120, 121
Eyelid
Blepharoplasty Yes No Yes 122-124
Ptosis repair Yes ? No 122
Glaucoma
Trabeculectomy Yes Yes Yes 125, 126
Others
Strabismus repair Yes No No 127
Therefore, we developed this Addendum to the 2014 DED Guidelines for Optometrists specifically to address 
the perisurgical management of DED. The focus here is on cataract surgery, mainly phacoemulsification with 
intraocular lens (IOL) implantation and refractive procedures such as laser-assisted in situ keratomileusis 
(LASIK). Comorbid DED in glaucoma is discussed in the sidebar on Dry Eye Disease in Glaucoma.
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DRY EYE DISEASE IN GL AUCOMA
DED is a common comorbidity with glaucoma, occurring in 15% to 59% of glaucoma patients.94-99 This as-
sociation can be explained at least in part by medicated eye drop polypharmacy, and specifically by the pres-
ence and duration of exposure to irritants found in medicated and non-medicated products, including active 
pharmaceutical ingredients and preservatives such as benzalkonium chloride (BAK).99, 100
Inflammation in response to BAK may be heightened by the presence of hyperosmolar tears,101 as is com-
mon in DED. Moreover, chronic use of BAK-containing products can lead to increased tear-film osmolarity, 
and DED can complicate ophthalmic surgery, including procedures for glaucoma.94 In patients using BAK-
containing products, a preoperative course of topical steroids may decrease conjunctival inflammation and 
increase the rate of successful trabeculectomy; of course, it is essential to monitor intraocular pressure if 
steroids are used.102, 103
Preservative-free artificial tears (ATs) are associated with reduced DED symptoms97 and should be used 
in preference to preserved ATs.8 However, it is rarely feasible for patients with glaucoma to avoid the use 
of irritating topical medications, especially as the disease progresses and topical monotherapy must be 
abandoned.100, 104, 105 For this reason, anti-inflammatory treatment may be considered, to ameliorate DED in 
patients requiring long-term exposure to topical glaucoma medications.106 Whereas it has been generally 
assumed that controlling glaucoma is the primary goal when these two conditions co-exist, recent find-
ings suggest that surface optimization in patients with comorbid glaucoma is compatible with reducing 
intraocular pressure.107, 108
Trabeculectomy and other surgeries for glaucoma temporarily exacerbate DED, but offer the prospect of 
long-term IOP control with greatly reduced need for topical glaucoma medications. Indeed, 40% of pa-
tients no longer require any topical glaucoma medications for up to 3 years post-trabeculectomy.109 With 
the advent of less-invasive surgical procedures, it may be possible to allow for better control of IOP at an 
earlier point in the progression of glaucoma, thus reducing the chronic exposure to irritating topical medi-
cations. So-called micro-invasive glaucoma surgeries (MIGS) are ab interno procedures, meaning that they 
are carried out from inside the eye and cause minimal or no trauma to the conjunctiva. MIGS procedures 
are considered sufficiently low risk that their use can be justified even in individuals with mild to moderate 
glaucoma.96 Although direct evidence is still lacking, MIGS procedures are therefore expected to carry less 
risk of inducing DED, compared to traditional surgery.
The general DED management approaches described in the Canadian Guidelines are considered to be applicable 
to patients requiring surgery. For this reason, this Addendum focuses on questions that are specific to perisurgical 
DED care, such as:
What evidence implicates uncontrolled DED in adverse post-surgical outcomes? 
How should the presence of DED affect decisions on the timing or appropriateness of a procedure? 
How should DED be managed before and after a procedure? 
How should optometrists and ophthalmologists co-manage DED in individuals being considered  
for ocular surgery?
DED, VISUAL FUNCTIONING, AND OCUL AR BIOMETRY
The precorneal tear film, the first refractive surface of the eye, functions best when mirror-smooth. The tear film is 
maintained by neuroendocrine mechanisms that regulate secretory function and the blink rate in response to shift-
ing environmental stresses.10, 26, 27 A healthy tear film is sufficiently thick, uniform, and balanced with appropriate 
components to protect the ocular surface from insult and to avoid optical aberrations between blinks.28-31
Abnormalities in the tear film, affecting either tear quantity or composition, can lead to aqueous-deficient or evapo-
rative ocular-surface diseases. Surgical trauma compromises tear-film regulation, at least temporarily. For example, 
loss of tactile sensation at surgically denervated sites in the cornea impairs basal and reflex tearing and reduces the 
blink rate, leading to a compromised tear film and ocular surface while the damaged nerves regrow.27, 32-34
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DED affects QoV without necessarily degrading visual acuity.1, 29, 35 For instance, DED is associated with glare, im-
paired contrast sensitivity and symptoms of higher order aberrations (HOAs); patients experience fluctuating vi-
sion during the interval between successive blinks, due to a non-uniform and unstable tear film.27 QoV is an impor-
tant predictor of daily function, especially for tasks that place high demands on the visual system such as reading 
or driving.36, 37
In patients undergoing ocular surgery, visual disturbances related to DED may increase the risk of postsurgical pa-
tient dissatisfaction. For both refractive procedures and cataract surgery with IOL implantation, surgical planning 
requires accurate keratometry and/or topography. Uncontrolled DED can alter the shape of the cornea,38 reducing 
the accuracy and precision of biometric findings. Tear hyperosmolarity is associated with greater statistical scatter 
in keratometric readings. Ocular-surface irregularity and instability reduce the precision of preoperative IOL and 
refractive calculations, increasing the risk of suboptimal refraction following surgery, especially when toric or mul-
tifocal implants are used.39 In addition, even for individuals who achieve good postsurgical acuity, DED can reduce 
QoV over a period of weeks to months, and sometimes longer.40
Table 2 summarizes various goals for DED treatment in the general population and in candidates for ocular surgery.
Table 2: Goals of DED management
For all individuals with DED For individuals with DED undergoing surgery
• To ameliorate eye discomfort and fatigue
• To prevent corneal erosion and surface anomalies  
 associated with ocular-surface disease and tear  
 hyperosmolarity3, 28, 32, 39
• To prevent optical aberrations that reduce visual  
 quality (e.g., blurring, glare, loss of contrast  
 sensitivity)30, 35
• To improve performance and facility in demanding  
 visual tasks (e.g., reading36 and driving37)
• To achieve more accurate and precise biometric/ 
 keratometric refractive measurements, allowing IOL power  
 or LASIK surface parameters to be calculated more  
 confidently
• To improve postsurgical visual acuity and quality of vision
• To prevent or minimize postsurgical DED40
The Growing Need for Collaborative Care for DED
Several demographic and societal trends have increased both the urgency and the burden of managing DED. 
First, both DED and ocular surgeries are increasingly common as the population ages. Second, the increasing 
reliance on and use of electronic devices can cause or exacerbate DED by decreasing the user’s blink rate.41, 
42 People who use these devices require a high level of visual functioning and may seek surgical intervention 
specifically to improve their QoV. Third, ophthalmic technology itself has changed with the introduction of 
measurement approaches that offer unprecedented precision in ocular biometry but that rely on a healthy tear 
film if they are to be used optimally. Likewise, multifocal and toric IOLs offer the prospect of corrected near 
and distance vision, but they appear to be more sensitive than earlier-generation IOLs to both visual aberra-
tions and errors in biometry.43 This difference is intrinsic to the IOL technology, but dissatisfaction also results 
in part from higher expectations, including the desire for optimal visual functioning with minimal dependence 
on distance or reading glasses.
For all of these reasons, the growing need for diligent pre- and postsurgical DED care is placing increasing demands 
on caregivers’ time. Efficient approaches, including collaborative DED management by optometrists and ophthal-
mologists, will be needed to meet these demands.
CATARACT SURGERY
If we extrapolate from 2014 data from a single province, approximately 450,000 phacoemulsification procedures 
may be carried out annually across Canada, making cataracts one of the most common reasons for ocular surgery.44, 45 
The demand for this surgery is projected to more than double by 2036.46
The current standard of care for cataract extraction is phacoemulsification followed by implantation of an IOL, 
which may be either monofocal or premium. The latter type of IOL includes a variety of designs that allow for cor-
rection of distance, reading, and intermediate vision, generally resulting in less dependence on glasses or contact 
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lenses. Depending on their design, premium IOLs may be prone to glare and halos, so it is important to minimize 
other visual disturbances in these patients, including aberrations related to DED.47, 48 Interestingly, cataracts them-
selves can induce HOAs,49, 50 and this effect on QoV is complicated by poorly controlled DED.29, 30
Pre-existing DED is common among individuals with cataracts, since some risk factors (notably advancing age, 
diabetes3, and female sex51) predispose patients to both conditions.52 However, DED commonly goes unrecognized 
and untreated in patients undergoing cataract surgery. Trattler et al. reported that, out of 136 American patients 
undergoing cataract surgery, while only 22% had a prior diagnosis of DED, a larger proportion showed objective 
signs of surface disease (tear break-up time (TBUT) ≤5 seconds, 63%; corneal staining, 77%) suggesting widespread 
underdiagnosis.25 Interestingly, subjective symptoms of DED were less common, with only 31% reporting stinging 
and 41% reporting foreign-body sensation. These findings are consistent with previous reports suggesting that pa-
tient self-reporting is an unreliable screening tool for DED.41, 53, 54
Uncontrolled DED limits the accuracy of preoperative biometry, leading to errors in IOL power or placement.41, 
54 This effect has been clearly demonstrated using repeated readings in patients presenting for cataract surgery. 
Epitropoulos et al. reported that the mean difference between two successive keratometric readings was 0.28 D 
among individuals with hyperosmolar tears (n=100 eyes) versus 0.13 D among controls (n=50 eyes). Calculated IOL 
power differences were up to 5.5 D among 100 eyes with hyperosmolar tears, and the frequency of an IOL power 
difference ≥0.5 D was significantly higher with hyperosmolar versus normal tears (p=0.02). In addition, 17% of 
eyes with hyperosmolar tears but only 2% of eyes with normal tears showed a vector astigmatism difference ≥1.0 D 
(p=0.01) between readings.39
Onset of Symptoms of DED Following Cataract Surgery
Cataract surgery perturbs the ocular surface and induces intraocular and ocular-surface inflammation. In ad-
dition, the surgical procedure damages sensory and other neurons, and the resulting denervation reduces tac-
tile and other sensation in the cornea.40 De novo DED symptoms are common following phacoemulsification,10, 
27 but they are usually transient. Corneal hypoesthesia, tear-film instability, and other indicators of DED often 
resolve within 3 months, probably associated with the beginning of axonal regrowth.18, 19 Corneal sensation 
gradually returns to near-preoperative levels over the course of 1 year.40 In a small subset of patients, however, 
DED symptoms persist indefinitely.20, 55 For instance, individuals with diabetes are at increased risk of severe 
and chronic postsurgical DED.56
Topical treatments should be applied consistently following surgery to limit the extent or duration of de novo 
DED.52 Used alongside topical steroids, lubricants have been reported to improve symptoms of DED and visual 
functioning, relative to standard postsurgical topical care alone.57, 58 Jee et al. directly compared the effects of 
preservative-free versus preserved steroid and lubricant eye drops after cataract surgery in 80 patients (80 
eyes) with pre-existing DED. In this prospective, open-label study, patients received the preservative-free or 
preserved products 4 times daily for 1 month and twice daily thereafter. By Month 1 following surgery, subjects 
who received the preservative-free topical treatment reported significantly less severe symptoms compared 
to those who received preserved treatment (p<0.05). By Month 2, objective DED measures (staining, tear-film 
stability, inflammatory markers, and conjunctival goblet cells) were significantly improved with preservative-
free treatment.59
Lubrication alone may be insufficient to manage the inflammation that drives chronic DED.60-62 This has been 
shown most clearly in a randomized, multi-centre study of 233 Chinese adults with moderate to severe DED 
at baseline. Patients were randomized to twice-daily application of cyclosporine 0.05% or the emulsion that 
serves as its vehicle, with no other treatment permitted except for artificial tears. Whereas both groups ex-
perienced significant symptomatic improvement over baseline, significantly greater improvement was seen 
in corneal staining at 4 and 8 weeks (p=0.025 and 0.05, respectively) and in the Schirmer score at 4 weeks 
(p=0.035) with cyclosporine versus vehicle.60 While no such vehicle-controlled study has been reported in a 
surgical setting, a prospective, contralaterally controlled study compared topical cyclosporine with saline in 
32 patients undergoing bilateral phacoemulsification. In these patients, treatment with topical cyclosporine 
significantly improved tear-film stability and other measures of DED, relative to saline alone. While patient-
reported DED intensity improved by the first month of treatment, clinical benefits became statistically signifi-
cant by 2 months of cyclosporine treatment.63
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  4 25
CLINICAL RESEARCHC
Exacerbation of DED after Cataract Surgery
For patients with pre-existing chronic DED, anti-inflammatory treatment may improve postsurgical acuity and vi-
sual functioning.47, 64 In a small, prospective, contralaterally controlled, randomized, double-masked study, Donnen-
feld et al. compared lubricating eye drops (0.4% polyethylene glycol 400; 0.3% propylene glycol) to topical cyclospo-
rine in patients undergoing bilateral phacoemulsification with multifocal IOL implantation. Of the 14 individuals 
studied, only 3 had been diagnosed as DED. However, because the mean baseline TBUT was low (approximately 
6 seconds), others may have had undiagnosed or marginal DED. Treatment was initiated 1 month before surgery 
and maintained after the procedure. By Month 2 following surgery (i.e., after 3 months of topical treatment), uncor-
rected visual acuity was significantly better for eyes treated with cyclosporine than with lubricants alone (p=0.005). 
Contrast sensitivity was also improved with cyclosporine treatment, and there was a numeric trend toward greater 
tear stability at Month 2. Furthermore, corneal staining, which worsened from baseline in lubricant-treated eyes, 
improved significantly in cyclosporine-treated eyes (p=0.034 for the between-group difference at Month 2).47
Other studies have explored the postsurgical use of topical cyclosporine in cataract surgery.63-65 It has been suggested 
that some treatment effects are seen within weeks of phacoemulsification65 and other surgeries,66 but these claims are 
difficult to evaluate, given that the established benefits of cyclosporine occur with longer-term use (≥3 months).8, 54, 61
REFRACTIVE SURGERY
LASIK and related photorefractive procedures are widely used to improve uncorrected visual acuity. These pro-
cedures generally lead to favorable outcomes and high patient satisfaction.67, 68 However, postoperative dry eye is a 
possible complication of these procedures and a cause of discomfort, reduced vision, and overall dissatisfaction. As 
with cataract surgery (above), DED following LASIK is associated with the effects of surgical trauma on the ocular 
surface, including loss of sensation in the cornea40 and suppression of blinking and both reflex and basal tearing.69 
Pre-existing DED is likely common and underdiagnosed, given that contact lens intolerance, which has been linked 
to DED, is a common motivator for patients requesting LASIK.67
Dry Eye Disease as a Factor in Patient Selection
Because refractive surgeries are elective, only individuals who have or can attain adequate ocular-surface health are 
considered candidates.2, 32, 70, 71 Severe DED due to SS or other immune causes is usually considered a contraindica-
tion for surgical refractive treatment. However, some reports suggest that even these individuals may be candidates 
for LASIK if the condition is successfully managed before the procedure.68, 72 To this end, pre-existing DED should 
be managed in a stepwise manner (Fig. 1), using therapies described in the 2014 Guidelines.8 Notably, one retrospec-
tive study found that cyclosporine treatment for an average of 3.2 months (range 1–12 months) enabled those with 
mild DED to proceed with refractive surgery.73
Alternative photorefractive surgeries, including flapless procedures such as small-incision lenticule extraction 
(SMILE), appear to cause less nerve damage and less severe DED than does LASIK.74, 75 Whether these newer pro-
cedures are preferable for patients at high risk of DED has not yet been established.69, 72
Transient versus Chronic DED Following LASIK
Following LASIK, tear-film instability and other DED signs and symptoms usually resolve spontaneously, but 
chronic postsurgical DED, persisting 6 to 12 months after LASIK, has been reported in 0.8% to 20% of patients.70, 76 
The risk of chronic post-LASIK DED increases with age and is greater in women than in men.71, 73 It has also been 
suggested that hyperopic LASIK procedures carry a greater risk of chronic DED than does myopic LASIK.73, 77, 78 Fol-
lowing hyperopic LASIK, patients with pre-existing DED and those who develop chronic DED appear to be at high 
risk of refractive regression.70, 77
In addition, pre-existing mild or subclinical DED appears to be a risk factor for chronic post-LASIK DED.32 One 
prospective study followed 139 eyes undergoing LASIK. Subjects were excluded if they had a definitive diagnosis of 
DED, but could be included with isolated symptoms such as mild or moderate corneal staining or TBUT<5 seconds. 
In this population, presurgical corneal staining and low tear production were associated with DED persisting 1 year 
after LASIK.76 Similarly, patients with reduced tear-film stability at baseline were at significantly greater risk of 
developing surface abnormalities over at least the first 6 months after LASIK.79
Use of topical cyclosporine following LASIK has been explored as a possible supplement to standard post-pro-
cedural care for patients with no prior diagnosis of DED. Peyman et al. reported that, in a series of 22 bilaterally 
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  7 9   NO.  426
RESEARCH
treated subjects, eyes receiving daily cyclosporine were significantly more likely to recover tactile sensitivity within 
3 months following LASIK, relative to control eyes (p≤0.011).80 The timing of this response is consistent with evi-
dence that the clinical benefits of cyclosporine become significant after ≥3 months of treatment.8, 61, 66
Post-LASIK visual acuity is less satisfactory among patients who develop chronic DED relative to patients who have 
no such adverse effect.70, 77, 78 In a large (n=565) retrospective analysis, Albietz et al. reported that refractive regres-
sion was associated with chronic DED (p=0.008 for DED at Month 12 vs no DED) and with pre-existing ocular-sur-
face staining, reduced TBUT, and reduced corneal tactile sensation.81 The authors noted that DED in their patients 
abated with persistent ocular-surface management, involving placement of lacrimal occlusion (punctal plugs), lid 
hygiene, and consistent use of lubricating eye drops. In eyes with evidence of post-LASIK DED, uncorrected visual 
acuity and DED signs and symptoms improved in parallel,81 as has been reported outside the surgical setting.82
Taken together, these findings suggest that individuals at risk of post-LASIK DED benefit from topical treatments 
that restore the tear film and target inflammation.
Exacerbation of DED after LASIK
Salib et al. tested pre-LASIK DED treatment using cyclosporine versus unpreserved artificial tears in patients 
with a history of DED (n=21 [42 eyes]).83 Those scheduled to undergo myopic LASIK began twice-daily treatment 
with the randomized drops 1 month before the procedure. For both of these treatments, corneal-surface staining 
and subjective DED symptoms improved by the time of the procedure. Topical treatment was maintained over 
the following 3 months. DED symptoms worsened transiently at the Week 1 observation, with faster recovery 
seen in the cyclosporine-treated eyes relative to eyes treated with artificial tears. From 3 to 12 months following 
LASIK, DED symptoms improved relative to the baseline evaluation in both treatment groups. Cyclosporine-
treated eyes showed greater predictability in refraction over the 1-year observation period and were more likely 
to be within 0.5 D of their target spherical equivalent refraction. This difference was statistically significant by 
Month 3 (p=0.015).83
If cyclosporine is to be used in individuals being considered for LASIK, treatment should begin ≥1 month before the 
procedure and should be maintained for ≥3 months afterwards, to maximize the benefit when DED symptoms are 
most troublesome. Pretreatment may allow individuals who would not otherwise be considered for refractive surgery 
to undergo LASIK successfully,32 and should be considered for those with evidence of mild or asymptomatic DED.66, 80
In addition to anti-inflammatory treatment,66, 80, 83 pre- and post-LASIK therapeutic options include a broad range of 
options discussed in the 2014 Guidelines,8 such as lubricating eye drops, scleral lenses, lacrimal occlusion, essential 
fatty acid supplementation,84, 85 autologous serum, and oral doxycycline. Perisurgical data on most of these options 
are highly limited. In one small study of 12 individuals with residual refractive errors after LASIK whose uncor-
rected vision improved with the application of lubricating artificial tears, punctal plugs appeared to improve visual 
performance significantly (p<0.0001).86 In addition, Di Pasquale et al. suggested that patients showing continued 
tear-film instability after ocular-surface inflammation has been addressed may benefit from an eye-warming pro-
cedure,87 to stimulate Meibomian gland secretion and restore tear lipids.8, 88 In an observational study on patients 
whose de novo DED persisted for 1 year after LASIK, the combination of punctal plugs, topical corticosteroids, and, 
where indicated, warm compresses, led to subjective symptomatic improvement in DED, as well as significant in-
creases in tear lipid thickness and TBUT.87
COLLABORATIVE MANAGEMENT OF DED
Table 3 lists a series of goals for pre- and postoperative treatment of patients who are being considered for 
ocular surgery. The list is general, in that it could apply equally to cataract and refractive surgery and poten-
tially to other procedures whose outcomes can be compromised by uncontrolled DED. Briefly, all patients who 
are referred for surgery consultation should be assessed carefully for symptoms and signs of ocular-surface 
disease. Patients with episodic or chronic DED should be treated prior to surgery with a goal of addressing 
both the signs and symptoms of DED and stabilizing the tear film and the ocular surface, to ensure that kera-
tometric and topographic data are reliable and precise. Appropriate counseling during this treatment period is 
also critical to improve the patient’s understanding of the condition and to manage expectations. After the pro-
cedure, ocular-surface disease may develop or worsen, at least transiently, despite the continued use of DED 
therapies initiated before surgery. The goal of care during this period should be to manage ocular discomfort 
and to restore a stable and healthy ocular surface.
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Table 3: Goals for pre- and post-surgical management of DED
In the preoperative setting, achieve: In the postoperative setting:
1. Minimal DED signs on exam 1. Maintain presurgical treatment if ocular surface is stable
2. Minimal and controlled discomfort
2. Otherwise, intensify treatment until ocular surface  
 is stable and returns to an adequate baseline
3. Stable, optimized tear film
4. Stable keratometric readings (biometric and topographic)
5. Stable manifest refraction
While the locus of care before and after surgery may vary somewhat based on the circumstances, in general, optometrists 
are well-placed to deliver much of the DED care that patients will require before and after surgery. DED is often detected 
first while the patient is under an optometrist’s care. Whether or not the patient is being considered for ocular surgery, 
the optometrist should assess the ocular surface and initiate appropriate treatment without delay. In all cases, the role 
of the tear film and ocular surface needs to be addressed with surgical candidates, to reinforce the need for good treat-
ment adherence and to avoid postsurgical disappointment. If premium IOLs are being considered, the patient should be 
informed that these devices are particularly sensitive to ocular-surface disturbance.
Figure 2 shows a schema for the efficient co-management of patients requiring or requesting ocular surgery, who 
have been diagnosed with symptomatic or asymptomatic DED. In such cases, the optometrist should describe in a 
referral letter to the surgeon all ocular-surface findings, including subjective reports and objective evidence leading 
to this diagnosis. Ideally, the optometrist will manage the condition at this early point, both to improve the patient’s 
immediate comfort and visual function and to streamline management of the surgery. The optometrist’s correspon-
dence should describe DED tests and treatments to date, as well as the outcome of these treatments. If appropriate, 
the optometrist may also recommend that the procedure be delayed to allow time to optimize the ocular surface.
Figure 2: Proposed schema for the co-management of perisurgical DED
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The ophthalmologist will schedule surgery if the ocular surface is stable and healthy or will refer the patient back 
to the optometrist for ongoing or enhanced DED treatment. In some cases, the optometrist may request that the 
ophthalmologist assume care of the patient, including management of the ocular surface/cornea. Following surgery, 
it is generally appropriate for ongoing DED care to shift back to the optometrist, unless recalcitrant disease or com-
plications manifest that require secondary or tertiary intervention. In a return report, the surgeon should describe 
the nature and outcomes of the procedure, as well as any changes that may have been made for postsurgical DED 
management, including changes in prescription and non-prescription topical treatments.
CONCLUSIONS
DED is a chronic inflammatory disorder that optometrists and ophthalmologists encounter on a routine basis. 
It should be assessed and appropriately treated in all patients. The principles of DED treatment are similar 
whether or not ocular surgery is being considered and should follow the recommendations of the 2014 Canadian 
Dry Eye Disease Guidelines.8 However, DED management is particularly important before and after certain 
surgical procedures, specifically refractive and cataract surgery, because uncontrolled DED may place the 
patient at risk of less-than-optimal surgical outcomes and, conversely, surgery commonly induces or exacerbates 
DED. Surgery should therefore be delayed until the ocular surface has been stabilized and an adequate and appro-
priate tear film is restored, to the maximum extent possible. As outlined in Figure 1, anti-inflammatory treatment 
for patients with pre-existing chronic DED should be initiated before surgery and maintained for some months 
afterwards. Consensus recommendations for the management of perisurgical DED are shown in Table 4.
Table 4: Consensus recommendations for the management of perisurgical DED
Recommendation 1. For patients with suspected ocular neuropathic pain, it is important to identify associated conditions, 
such as non-ocular neuropathic pain, depression, anxiety, and sleep disorders.
Recommendation 2. Depending on frequency of use, preservative-free formulations of medicated and non-medicated topical 
products should be considered for use before and after ocular surgery.
Recommendation 3. Independent of self-reported eye discomfort, patients undergoing cataract surgery should be assessed for 
signs and symptoms of DED.
Recommendation 4. The ocular surface should be optimized prior to cataract surgery, to increase the accuracy and precision 
of preoperative biometry and to improve postoperative comfort and visual functioning.
Recommendation 5. Patients with pre-existing symptomatic or asymptomatic DED should be considered for treatment with 
anti-inflammatory agents prior to surgery, to prevent exacerbation of symptoms.
Recommendation 6. A dedicated DED assessment should be conducted as part of work-up in all patients being considered for 
refractive surgery.
Recommendation 7. Signs and symptoms of chronic DED, including mild DED, should be evaluated and managed in all 
candidates for ocular surgery.
Recommendation 8. Patients with ocular-surface staining, tear-film instability, or other signs of DED should be counselled 
about the risk of exacerbation of DED following ocular surgery.
Recommendation 9. Irrespective of any prior history of DED, patients undergoing ocular surgery should be counselled that 
DED symptoms can occur following the procedure.
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Efficient perisurgical care for patients with DED requires that optometrists and ophthalmologists co-manage the 
condition and communicate effectively with one another and provide consistent messages to the patient about the 
ocular-surface findings, risks, and response to treatment. Checklists describing best practices for correspondence 
between the surgeon and the optometrist are provided in Supplementary Table 1.
Supplementary Table 1: DED-related information to include in cross-referrals between optometrists and ophthalmologists
Optometrist to ophthalmologist Ophthalmologist back to optometrist
Sy
m
pt
om
s
• Sensation
Indicate
timeline
• Vision
• Sensation
• Vision
• Description of recent surgical procedure
• Outcomes (include postsurgical refraction if done)
Si
gn
s/
as
se
ss
m
en
t
Findings
• Symptom score (questionnaire)
• Tear stability (NIBUT/TBUT)
• Corneal (NaFl) and conjunctival staining (LG)
• Meibomian gland function
• Other testing (e.g., tear osmolarity)
Description of DED/ocular surface
• Severity
• Currently stable? (if Yes, how long since stability achieved?)
M
an
ag
em
en
t • Current and past treatments
• Tolerability issues, if any
• Adherence history
• Any postsurgical changes made to ocular-surface  
 management, including non-prescription products?  
 (if Yes, specify products and dosing)
R
ec
om
m
en
da
ti
on
s • Should the patient be scheduled  
 for the earliest possible surgery?
• If No, what therapeutic milestones  
 should be achieved before scheduling  
 surgery?
• Instructions for postsurgical care
• Next scheduled clinic visit or returning to optometrist’s  
 care or co-management
• Patient’s goals for vision
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